Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 13th January 2021
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer announces collaboration with PetMedix
PetMedix's Ky9 platform can rapidly and efficiently generate fully canine therapeutic antibodies.
Partnership will see the development of companion animal antibody therapeutics.

Boehringer Ingelheim has announced a multi-year partnership with PetMedix - a Cambridge-based biopharmaceutical firm - to develop novel and transformative companion animal antibody therapeutics.

The collaboration will see PetMedix undertake discovery activities against a number of key targets and Boehringer Ingelheim will work to develop and bring these therapies to market. The terms of the partnership have not been disclosed. 

PetMedix’s breakthrough approach to therapeutic antibodies has resulted in a number of successful, novel therapies for humans. It is also the only company in the world that has been able to bring this approach to veterinary medicine.

Through its its Ky9™ platform, PetMedix can rapidly and efficiently generate fully canine therapeutic antibodies. This approach saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies.

Dr Tom Weaver, CEO of PetMedix, said: “We are excited to be working with Boehringer Ingelheim on this project as we feel we bring complementary experience and expertise to this partnership. PetMedix has developed the leading pet antibody discovery engine, and it will be through Boehringer Ingelheim’s global scale and industry leadership that these novel therapies will best be able to succeed and ultimately benefit the animals.”

James Allan, global head of transaction, business development & licensing, Boehringer Ingelheim Animal Health, added: “Boehringer Ingelheim is pleased to be working with PetMedix on this cutting edge technology as a means to bring innovative new therapies to improve the health of animals globally. PetMedix has a unique expertise and its focus on innovation aligns well with our own”.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.